Indian pharmaceutical companies could face losses of up to $750 million if the ongoing conflict in West Asia continues to disrupt trade flows, logistics networks, and demand across key markets in the region.
West Asia remains a crucial destination for India’s drug exports, accounting for a significant share of formulations, generic medicines, and hospital supplies. Prolonged instability has begun to impact supply chains, with delays in shipments, rising freight costs, and payment uncertainties emerging as key concerns for exporters.
Industry stakeholders report that several consignments have already been delayed due to disruptions in major shipping routes and air cargo corridors. Heightened security risks and insurance premiums are further adding to operational costs, squeezing margins for Indian drugmakers.
The region’s dependence on imported pharmaceuticals makes it a vital market for Indian firms, particularly for countries such as the UAE, Saudi Arabia, and Iraq. However, ongoing geopolitical tensions have slowed procurement cycles, with distributors and healthcare providers adopting a cautious approach amid uncertainty.
Exporters are also facing challenges related to currency volatility and delayed receivables, which could strain working capital if the situation persists. Smaller and mid-sized pharmaceutical companies are expected to be more vulnerable due to limited financial buffers.
Analysts note that if disruptions extend over the coming months, companies may be forced to reroute shipments, explore alternative markets, or adjust production plans to mitigate risks. Some firms are already evaluating diversification strategies to reduce dependence on conflict-prone regions.
Despite the near-term headwinds, India’s pharmaceutical sector is expected to remain resilient, supported by strong global demand for affordable medicines. However, the duration and intensity of the West Asia conflict will be critical in determining the extent of financial impact on exporters.